BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 31678168)

  • 1. PD-L1
    Zhang L; Zhang X; Liu Y; Zhang T; Wang Z; Gu M; Li Y; Wang DD; Li W; Lin PP
    Cancer Lett; 2020 Jan; 469():355-366. PubMed ID: 31678168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas.
    Li M; Gao F; Ren X; Dong G; Chen H; Lin AY; Wang DD; Liu M; Lin PP; Shen S; Jiang H; Yang C; Zhang X; Zhao X; Zhu Q; Li M; Cui Y; Lin S
    Cancer Sci; 2022 Oct; 113(10):3535-3546. PubMed ID: 35940591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
    Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A
    Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aneuploid subtypes of circulating tumor cells and circulating tumor-derived endothelial cells predict the overall survival of advanced lung cancer.
    Zhang J; Hong Y; Wang L; Hu W; Tian G; Wu D; Wang Y; Dai L; Zhang Z; Yang Y; Fang J
    Front Oncol; 2023; 13():829054. PubMed ID: 37213309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal detection of subcategorized CD44v6
    Wang Y; Zhang L; Tan J; Zhang Z; Liu Y; Hu X; Lu B; Gao Y; Tong L; Liu Z; Zhang H; Lin PP; Li B; Gires O; Zhang T
    Cancer Lett; 2023 Sep; 571():216337. PubMed ID: 37553013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of aneuploid circulating tumor cells and CD31
    Zhang T; Zhang L; Gao Y; Wang Y; Liu Y; Zhang H; Wang Q; Hu F; Li J; Tan J; Wang DD; Gires O; Lin PP; Li B
    Mol Oncol; 2021 Nov; 15(11):2891-2909. PubMed ID: 34455700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aneuploid Circulating Tumor-Derived Endothelial Cell (CTEC): A Novel Versatile Player in Tumor Neovascularization and Cancer Metastasis.
    Lin PP
    Cells; 2020 Jun; 9(6):. PubMed ID: 32599893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.
    Nicolazzo C; Raimondi C; Mancini M; Caponnetto S; Gradilone A; Gandini O; Mastromartino M; Del Bene G; Prete A; Longo F; Cortesi E; Gazzaniga P
    Sci Rep; 2016 Aug; 6():31726. PubMed ID: 27553175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC.
    Kloten V; Lampignano R; Krahn T; Schlange T
    Cells; 2019 Aug; 8(8):. PubMed ID: 31374957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
    Ilié M; Szafer-Glusman E; Hofman V; Chamorey E; Lalvée S; Selva E; Leroy S; Marquette CH; Kowanetz M; Hedge P; Punnoose E; Hofman P
    Ann Oncol; 2018 Jan; 29(1):193-199. PubMed ID: 29361135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tracking circulating PD-L1-positive cells to monitor the outcome of patients with gastric cancer receiving anti-HER2 plus anti-PD-1 therapy.
    Chong X; Li Y; Lu J; Feng X; Li Y; Zhang X
    Hum Cell; 2024 Jan; 37(1):258-270. PubMed ID: 37889437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer.
    Dong J; Zhu D; Tang X; Lu D; Qiu X; Li B; Lin D; Li L; Liu J; Zhou Q
    PLoS One; 2019; 14(7):e0220306. PubMed ID: 31348821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis.
    Zhu HH; Liu YT; Feng Y; Zhang LN; Zhang TM; Dong GL; Xing PY; Wang HY; Shi YK; Hu XS
    Thorac Cancer; 2021 Oct; 12(20):2749-2757. PubMed ID: 34423906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
    Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB
    Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273
    [No Abstract]   [Full Text] [Related]  

  • 15. Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.
    Koh Y; Yagi S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Higuchi M; Kanbara H; Nakanishi M; Ueda H; Yamamoto N
    Clin Lung Cancer; 2019 Jul; 20(4):270-277.e1. PubMed ID: 31005568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined detection of aneuploid circulating tumor-derived endothelial cells and circulating tumor cells may improve diagnosis of early stage non-small-cell lung cancer.
    Lei Y; Sun N; Zhang G; Liu C; Lu Z; Huang J; Zhang C; Zang R; Che Y; Mao S; Fang L; Wang X; Zheng S; He J
    Clin Transl Med; 2020 Jul; 10(3):e128. PubMed ID: 32659050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations.
    Sato M; Watanabe S; Tanaka H; Nozaki K; Arita M; Takahashi M; Shoji S; Ichikawa K; Kondo R; Aoki N; Hayashi M; Ohshima Y; Koya T; Ohashi R; Ajioka Y; Kikuchi T
    PLoS One; 2019; 14(4):e0215292. PubMed ID: 30978241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer.
    Zhou Q; Liu X; Li J; Tong B; Xu Y; Chen M; Liu X; Gao X; Shi Y; Zhao J; Zhong W; Wang M
    Thorac Cancer; 2023 Feb; 14(5):470-478. PubMed ID: 36630992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Herzberg B; Campo MJ; Gainor JF
    Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer.
    Sinoquet L; Jacot W; Gauthier L; Pouderoux S; Viala M; Cayrefourcq L; Quantin X; Alix-Panabières C
    Clin Chem; 2021 Nov; 67(11):1503-1512. PubMed ID: 34355741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.